CN112794908A - Preparation and analysis method of anti-HLA-G antibody - Google Patents
Preparation and analysis method of anti-HLA-G antibody Download PDFInfo
- Publication number
- CN112794908A CN112794908A CN202011645505.5A CN202011645505A CN112794908A CN 112794908 A CN112794908 A CN 112794908A CN 202011645505 A CN202011645505 A CN 202011645505A CN 112794908 A CN112794908 A CN 112794908A
- Authority
- CN
- China
- Prior art keywords
- hla
- antibody
- producing
- monoclonal antibody
- ascites
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004458 analytical method Methods 0.000 title claims description 11
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 8
- 230000003053 immunization Effects 0.000 claims abstract description 7
- 239000000427 antigen Substances 0.000 claims abstract description 6
- 108091007433 antigens Proteins 0.000 claims abstract description 6
- 102000036639 antigens Human genes 0.000 claims abstract description 6
- 238000002649 immunization Methods 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 15
- 238000002965 ELISA Methods 0.000 claims description 11
- 206010003445 Ascites Diseases 0.000 claims description 10
- 210000004408 hybridoma Anatomy 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 230000008878 coupling Effects 0.000 claims description 9
- 238000010168 coupling process Methods 0.000 claims description 9
- 238000005859 coupling reaction Methods 0.000 claims description 9
- 210000000349 chromosome Anatomy 0.000 claims description 7
- 238000000684 flow cytometry Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 238000011725 BALB/c mouse Methods 0.000 claims description 4
- 238000007865 diluting Methods 0.000 claims description 4
- 230000035945 sensitivity Effects 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 108010078791 Carrier Proteins Proteins 0.000 claims description 3
- 102000014914 Carrier Proteins Human genes 0.000 claims description 3
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 229920002866 paraformaldehyde Polymers 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 238000011002 quantification Methods 0.000 claims description 3
- 210000004989 spleen cell Anatomy 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 238000007796 conventional method Methods 0.000 claims description 2
- 230000003187 abdominal effect Effects 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 238000004321 preservation Methods 0.000 claims 2
- 239000007928 intraperitoneal injection Substances 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to a method for preparing and analyzing an anti-HLA-G antibody, which comprises the following steps: (1) preparation of antigen for immunization (2) preparation of anti-HLA-G monoclonal antibody.
Description
Technical Field
The invention relates to the field of antibody preparation, in particular to a preparation and analysis method of an anti-HLA-G antibody.
Background
Human leukocyte antigen G (HLA-G) belongs to the non-classical HLA class I molecule and was first cloned by Geright in 1987. At present, the inhibition function of HLA-G on the body immune system is proved, and the HLA-G can be directly combined with inhibitory receptors immunoglobulin-like transcripts, immunoglobulin-like transcripts and killer cells immunoglobulin-like receptors on the surfaces of immune cells such as T lymphocytes, B lymphocytes, NK cells and the like to exert biological activity. Under physiological conditions, HLA-G is mainly expressed in cells and tissues such as villous ectotrophoblast cells, adult thymus medullary tissues, corneal cells, pancreatic islets, epithelioid progenitor cells and the like; in pathological conditions, HLA-G can be produced in tumors, organ transplants, autoimmune diseases, and the like. On one hand, the expression of HLA-G can reduce or inhibit the immune response reaction of the body to the pregnant and organ transplant recipients, induce the formation of immune tolerance of the body, and is beneficial to the continuation of pregnancy and the long-term survival of transplanted organs; on the other hand, HLA-G can help tumor cells avoid the immune response of a host, so that the tumor is easy to metastasize and seriously harms the body health of a patient.
Disclosure of Invention
The invention aims to provide a preparation method of an anti-HLA-G antibody.
The technical scheme for achieving the purpose of the invention is as follows.
Preparing antigen for immunization, and coupling the synthesized polypeptide to carrier protein. Purifying the coupled product by column, directly measuring protein concentration by direct quantification (UV method) at 280nm wavelength, packaging, and storing at-40 deg.C. Polypeptide coupling protein (KLH, BSA, OVA and the like), polypeptide-KLH coupling matter is used for immunizing mice, and polypeptide-BSA coupling matter is used for detecting the titer of mouse serum, hybridoma supernatant and ascites anti-HLA-G monoclonal antibody.
Preparing anti-HLA-G monoclonal antibody, separating BALB/c mouse spleen cell after 3 times of immunization and fusing with Sp2/0 cell by polyethylene glycol conventional method. Positive clones tested by ELISA were subcloned by limiting dilution until the positive rate of wells with clonally grown reached 100%. The titer of the monoclonal antibody of the hybridoma supernatant for resisting HLA-G is detected by indirect ELISA. Washing hybridoma cells by PBS buffer solution, then resuspending, injecting by 0.5 multiplied by 106-5 multiplied by 106 per abdominal cavity, collecting ascites of mice after 9 days, and preserving at-20 ℃ for later use.
Characteristic analysis of the anti-HLA-G monoclonal antibody, and chromosome counting under a microscope after the genetics identification of the anti-HLA-G monoclonal antibody cell strain is made by a common chromosome flaking method. The determination of the antibody sensitivity identification is carried out by diluting the ascites of the anti-HLA-G monoclonal antibody according to the ratio of 1: 53-1: 510 and then carrying out an indirect ELISA test. Specific analysis of anti-HLA-G monoclonal antibody Flow Cytometry (FCM) detection and fluorescence microscopy were carried out after 40G/L paraformaldehyde fixation of JEC-3 cell line and Peripheral Blood Lymphocytes (PBLs).
The above-mentioned raw materials, reagents and the like are commercially available.
The invention can be used for preparing an anti-HLA-G antibody and provides an analysis method.
Drawings
FIG. 1 is a graph of the absorbance of monoclonal antibody proteins.
FIG. 2 is a graph showing the results of flow cytometry.
Detailed Description
The technical solution of the present invention will be further described in non-limiting detail with reference to the following embodiments. It should be noted that the following embodiments are only for illustrating the technical concept and features of the present invention, and the purpose of the present invention is to enable those skilled in the art to understand the content of the present invention and implement the present invention, and not to limit the protection scope of the present invention. All equivalent changes and modifications made according to the spirit of the present invention should be covered within the protection scope of the present invention.
The invention provides a preparation and analysis method of an anti-HLA-G antibody. The technical solution of the present invention is further illustrated by the following examples
1. Preparation of antigens for immunization
The first step couples the synthesized polypeptide to a carrier protein. Purifying the coupled product by column, directly measuring protein concentration by direct quantification (UV method) of protein at 280nm, subpackaging, and storing at-40 deg.C for use. The polypeptide coupling protein (KLH, BSA, OVA and the like), the polypeptide-KLH coupling protein is used for immunizing mice, and the polypeptide-BSA coupling protein is used for detecting the titer of mouse serum, hybridoma supernatant and ascites anti-HLA-G monoclonal antibody.
2. Preparation of anti-HLA-G monoclonal antibody
3 immunized BALB/c mouse splenocytes were isolated and fused with Sp2/0 cells using polyethylene glycol protocol. Positive clones tested by ELISA were subcloned by limiting dilution until the positive rate of wells with clonally grown reached 100%. The titer of the monoclonal antibody of the hybridoma supernatant for resisting HLA-G is detected by indirect ELISA. Washing hybridoma cells by PBS buffer solution, then resuspending, injecting into abdominal cavity by 0.5 × 106-5 × 106 cells/cell, collecting mouse ascites after 9 days, and preserving at-20 ℃ for later use.
3. Characterization of anti-HLA-G monoclonal antibodies
Genetic identification of anti-HLA-G monoclonal antibody cell lines was performed by sectioning using a common chromosome sectioning method and counting chromosomes under a microscope. The determination of the antibody sensitivity identification is carried out by diluting the ascites of the anti-HLA-G monoclonal antibody according to the ratio of 1: 53-1: 510 and then carrying out an indirect ELISA test. Specific analysis of anti-HLA-G monoclonal antibody Flow Cytometry (FCM) detection and fluorescence microscopy were carried out after 40G/L paraformaldehyde fixation of JEC-3 cell line and Peripheral Blood Lymphocytes (PBLs).
And (4) analyzing results:
1. production results of anti-HLA-G monoclonal antibody
In the present study, 6 BALB/c mice were immunized in total, and the results of the detection titer of the pre-fusion immune double amplification were as follows: 2 pieces of the Chinese herbal medicine are respectively added at a ratio of 1: 16, 1: 8 and 1: 2. 1 of the 1 strain hybridomas which stably secrete the antibody are obtained after 1 mouse spleen cell with the titer of 1: 16 is fused with a mouse myeloma cell SP2/0, screened, cloned and purified.
2. Results of analysis of anti-HLA-G monoclonal antibody characteristics
The chromosome population of the hybridoma was 93. The sensitivity of the anti-HLA-G monoclonal antibody was 1X 56 as measured by indirect ELISA. Recognizes HLA-G molecules but does not recognize other classical human leukocyte antigen class I molecules on human peripheral blood lymphocytes. This strain was initially described above as having HLA-G specificity.
Claims (8)
1. A method for producing an anti-HLA-G antibody, comprising the steps of:
(1) preparing an antigen for immunization:
coupling the synthesized polypeptide to carrier protein, purifying the coupling product through a column, directly testing the protein concentration by using the direct quantification (UV method) of the protein at the wavelength of 280nm, subpackaging and storing for later use;
(2) preparing an anti-HLA-G monoclonal antibody:
separating BALB/c mouse spleen cells immunized for 3 times, fusing with Sp2/0 cells by adopting a polyethylene glycol conventional method, subcloning positive clones detected by ELISA until the positive rate of a hole with clone growth reaches 100%, detecting the titer of the hybridoma supernatant anti-HLA-G monoclonal antibody by adopting indirect ELISA, washing the hybridoma cells by PBS buffer solution, then carrying out resuspension and intraperitoneal injection, collecting mouse ascites after a period of time, and storing for later use to prepare the anti-HLA-G antibody.
2. The method for producing an anti-HLA-G antibody according to claim 1,
the preservation in the step (1) is carried out at the temperature of minus 40 ℃.
3. The method for producing an anti-HLA-G antibody according to claim 1,
the preservation in the step (2) is carried out at the temperature of-20 ℃.
4. The method for producing an anti-HLA-G antibody according to claim 1,
in step (2), positive clones tested by ELISA were subcloned by limiting dilution.
5. The method for producing an anti-HLA-G antibody according to claim 1,
in the step (2), the preferred number of the abdominal injections is 0.5 × 106-5 × 106 per abdominal injection.
6. The method for producing an anti-HLA-G antibody according to claim 1,
the time for collecting ascites from the mouse in the step (2) is preferably 9 days later.
7. An analysis method for an anti-HLA-G antibody, comprising the steps of:
after being sliced by a common chromosome slice making method, chromosomes are counted under a microscope, the determination of antibody sensitivity identification is carried out by diluting ascites of an anti-HLA-G monoclonal antibody and then carrying out an indirect ELISA test, and the specificity analysis of the anti-HLA-G monoclonal antibody is carried out by fixing a JEC-3 cell strain and Peripheral Blood Lymphocytes (PBL) by 40G/L paraformaldehyde and then carrying out Flow Cytometry (FCM) detection and fluorescence microscope detection.
8. The method for analyzing anti-HLA-G antibody according to claim 7,
diluting ascites according to the proportion of 1: 53-1: 510.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011645505.5A CN112794908A (en) | 2020-12-31 | 2020-12-31 | Preparation and analysis method of anti-HLA-G antibody |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011645505.5A CN112794908A (en) | 2020-12-31 | 2020-12-31 | Preparation and analysis method of anti-HLA-G antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112794908A true CN112794908A (en) | 2021-05-14 |
Family
ID=75807649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011645505.5A Pending CN112794908A (en) | 2020-12-31 | 2020-12-31 | Preparation and analysis method of anti-HLA-G antibody |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112794908A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023184733A1 (en) * | 2022-03-31 | 2023-10-05 | 台州恩泽医疗中心(集团) | Monoclonal antibody against hla-g molecules and use thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1718588A (en) * | 2004-10-26 | 2006-01-11 | 四川新创生物科技有限公司 | Monoclone antibody for anti HLA-G and hybrid tumour cell secreting same, cancer dignosis method, diagnosis reagent box and its application |
| CN101928700A (en) * | 2009-07-28 | 2010-12-29 | 北京恒宇视野生物科技有限公司 | Protein kinase PFTK1 monoclonal antibody and preparation method thereof |
| WO2017207775A1 (en) * | 2016-06-03 | 2017-12-07 | Invectys | Anti hla-g specific antibodies |
-
2020
- 2020-12-31 CN CN202011645505.5A patent/CN112794908A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1718588A (en) * | 2004-10-26 | 2006-01-11 | 四川新创生物科技有限公司 | Monoclone antibody for anti HLA-G and hybrid tumour cell secreting same, cancer dignosis method, diagnosis reagent box and its application |
| CN101928700A (en) * | 2009-07-28 | 2010-12-29 | 北京恒宇视野生物科技有限公司 | Protein kinase PFTK1 monoclonal antibody and preparation method thereof |
| WO2017207775A1 (en) * | 2016-06-03 | 2017-12-07 | Invectys | Anti hla-g specific antibodies |
Non-Patent Citations (2)
| Title |
|---|
| 刘君星等, 黑龙江科学技术出版社 * |
| 陆盛军等: "抗HLA-G单克隆抗体G11E5的制备", 《细胞与分子免疫学杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023184733A1 (en) * | 2022-03-31 | 2023-10-05 | 台州恩泽医疗中心(集团) | Monoclonal antibody against hla-g molecules and use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111051347B (en) | TIGIT antibody, antigen-binding fragment thereof, and medical use thereof | |
| CN1021257C (en) | Isolation of fetal cells from maternal blood to enable prenatal diagnosis | |
| EP2195346B1 (en) | Dendritic cell marker and uses thereof | |
| JP5202501B2 (en) | Anti-C5aR antibody and use thereof | |
| CN105801701B (en) | The heavy chain and light chain variable region of a kind of PCSK9 antibody and its application | |
| JP2022512954A (en) | NKG2A antibody and its production method and use | |
| CN105112375B (en) | Hybridoma cell strain ZJED0-02, anti-Ebola virus GP protein monoclonal antibody and its preparation and application | |
| CN111744007A (en) | anti-TIGIT antibody pharmaceutical composition and application thereof | |
| WO2006132272A1 (en) | Method for production of antibody | |
| CN107987164B (en) | Estrogen receptor ER-alpha 36 antigen polypeptide and monoclonal antibody thereof | |
| CN112794908A (en) | Preparation and analysis method of anti-HLA-G antibody | |
| EA015897B1 (en) | Use of human monoclonal antibody to il-15 comprising a composition and medical preparation (variants), composition and medical preparation containing them | |
| JPS60228421A (en) | Monoclonal anti-human-igg antibody and its preparation | |
| US20200166512A1 (en) | Composition and methods for detecting cancer | |
| CN114605536B (en) | Affinity purification method for reducing host cell protein content in production of anti-human thymus stroma lymphopoietin monoclonal antibody | |
| CN112795543B (en) | Hybridoma cell strain, monoclonal antibody secreted by hybridoma cell strain and resisting grass carp IL-15R alpha and application of monoclonal antibody | |
| JP2002171971A (en) | Antigen and monoclonal antibody for identifying the antigen | |
| CN114874309B (en) | TEX101 recombinant protein and application thereof in preparation of monoclonal antibody | |
| CN114920837B (en) | Anti-cryptococcus capsular polysaccharide monoclonal antibody and application thereof | |
| CN114933652B (en) | Anti-candida mannan monoclonal antibody and application thereof | |
| TWI811787B (en) | Anti-kynurenine-3-monooxidase antibody molecule and composition, nucleic acid molecule, and host cell comprising the same as well as production method thereof | |
| CN114213542B (en) | CPS-I antibodies and uses thereof | |
| CN112608907B (en) | Phosphatidylinoglycan 3 monoclonal antibody, hybridoma cell strain and application | |
| CN112851811B (en) | CD44V6 nano antibody and application thereof as leukemia research reagent | |
| CN108659128B (en) | Monoclonal antibody of anti-CD 19 protein, cell strain, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20220307 Address after: 255000 room 1610, block B, polymer material industrial innovation park, No. 51, Lutai Avenue, high tech Zone, Zibo City, Shandong Province Applicant after: Shandong Guanke Biotechnology Co.,Ltd. Address before: 311300 room 802-812, building 1, science and technology building, 958 Dayuan Road, Qingshanhu street, Lin'an District, Hangzhou City, Zhejiang Province Applicant before: Hangzhou Binghu Biotechnology Co.,Ltd. |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210514 |